Canakinumab - Novartis
Alternative Names: ACZ-885; Anti-IL-1 beta monoclonal antibody; Antibody A; IlarisLatest Information Update: 22 Aug 2024
At a glance
- Originator Novartis
- Developer Charite - Universitatsmedizin Berlin; Columbia University; Novartis; Triemli hospital; University Hospital Tubingen; University Hospital Zurich
- Class Anti-inflammatories; Antianaemics; Antigouts; Antihyperglycaemics; Antineoplastics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Heart failure therapies; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Adult-onset Still's disease; Cryopyrin-associated periodic syndromes; Familial autosomal dominant periodic fever; Familial Mediterranean fever; Gouty arthritis; Juvenile rheumatoid arthritis; Peroxisomal disorders
- Preregistration Cardiovascular disorders
- Phase III Behcet's syndrome; COVID 2019 infections; COVID-19 pneumonia; Cytokine release syndrome; Non-small cell lung cancer
- Phase II Abdominal aortic aneurysm; Alcoholic hepatitis; Alzheimer's disease; Atherosclerosis; Heart failure; Malignant melanoma; Mild cognitive impairment; Myelodysplastic syndromes; Osteoarthritis; Peripheral arterial occlusive disorders; Pulmonary sarcoidosis; Respiratory insufficiency; Schnitzler syndrome; Sickle cell anaemia
- No development reported Chronic obstructive pulmonary disease; Pancreatic cancer; Renal cell carcinoma; Triple negative breast cancer
- Discontinued Asthma; Diabetic retinopathy; Polymyalgia rheumatica; Rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 09 Aug 2024 Novartis terminates a phase-II trial in Osteoarthritis in USA, Czechia, Estonia, Germany, Hungary, Latvia, Lithuania and Poland, due to sponsor decision (Intra-articular, Injection) (NCT04814368) (EudraCT2020-003631-21)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Second-line therapy or greater) in Australia (SC)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Second-line therapy or greater) in Israel (SC)